Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2023; 13(12):4004-4015. doi:10.7150/thno.84865 This issue Cite

Research Paper

Click-to-Release: Cleavable Radioimmunoimaging with [89Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio

Maria Vlastara1, Raffaella Rossin1, Freek J.M. Hoeben2, Kim E. de Roode1, Milou Boswinkel3, Laurens H.J. Kleijn1, James Nagarajah3, Mark Rijpkema3, Marc S. Robillard1✉

1. Tagworks Pharmaceuticals, Toernooiveld 1, 6525 ED Nijmegen, The Netherlands.
2. SyMO-Chem, Den Dolech 2, 5612 AZ Eindhoven, The Netherlands.
3. Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.

✉ Corresponding author: M.S.R. (email: marc.robillardcom)

Citation:
Vlastara M, Rossin R, Hoeben FJM, de Roode KE, Boswinkel M, Kleijn LHJ, Nagarajah J, Rijpkema M, Robillard MS. Click-to-Release: Cleavable Radioimmunoimaging with [89Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio. Theranostics 2023; 13(12):4004-4015. doi:10.7150/thno.84865. https://www.thno.org/v13p4004.htm
Other styles

File import instruction

Abstract

Graphic abstract

One of the main challenges of PET imaging with 89Zr-labeled monoclonal antibodies (mAbs) remains the long blood circulation of the radiolabeled mAbs, leading to high background signals, decreasing image quality. To overcome this limitation, here we report the use of a bioorthogonal linker cleavage approach (click-to-release chemistry) to selectively liberate [89Zr]Zr-DFO from trans-cyclooctene-functionalized trastuzumab (TCO-Tmab) in blood, following the administration of a tetrazine compound (trigger) in BT-474 tumor-bearing mice.

Methods: We created a series of TCO-DFO constructs and evaluated their performance in [89Zr]Zr-DFO release from Tmab in vitro using different trigger compounds. The in vivo behavior of the best performing [89Zr]Zr-TCO-Tmab was studied in healthy mice first to determine the optimal dose of the trigger. To find the optimal time for the trigger administration, the rate of [89Zr]Zr-TCO-Tmab internalization was studied in BT-474 cancer cells. Finally, the trigger was administered 6 h or 24 h after [89Zr]Zr-TCO-Tmab- administration in tumor-bearing mice to liberate the [89Zr]Zr-DFO fragment. PET scans were obtained of tumor-bearing mice that received the trigger 6 h post-[89Zr]Zr-TCO-Tmab administration.

Results: The [89Zr]Zr-TCO-Tmab and trigger pair with the best in vivo properties exhibited 83% release in 50% mouse plasma. In tumor-bearing mice the tumor-blood ratios were markedly increased from 1.0 ± 0.4 to 2.3 ± 0.6 (p = 0.0057) and from 2.5 ± 0.7 to 6.6 ± 0.9 (p < 0.0001) when the trigger was administered at 6 h and 24 h post-mAb, respectively. Same day PET imaging clearly showed uptake in the tumor combined with a strongly reduced background due to the fast clearance of the released [89Zr]Zr-DFO-containing fragment from the circulation through the kidneys.

Conclusions: This is the first demonstration of the use of trans-cyclooctene-tetrazine click-to-release chemistry to release a radioactive chelator from a mAb in mice to increase tumor-to-blood ratios. Our results suggest that click-cleavable radioimmunoimaging may allow for substantially shorter intervals in PET imaging with full mAbs, reducing radiation doses and potentially even enabling same day imaging.

Keywords: radioimmunoimaging, IEDDA, click-to-release, trans-cyclooctene, trastuzumab

Citation styles

APA
Vlastara, M., Rossin, R., Hoeben, F.J.M., de Roode, K.E., Boswinkel, M., Kleijn, L.H.J., Nagarajah, J., Rijpkema, M., Robillard, M.S. (2023). Click-to-Release: Cleavable Radioimmunoimaging with [89Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio. Theranostics, 13(12), 4004-4015. https://doi.org/10.7150/thno.84865.

ACS
Vlastara, M.; Rossin, R.; Hoeben, F.J.M.; de Roode, K.E.; Boswinkel, M.; Kleijn, L.H.J.; Nagarajah, J.; Rijpkema, M.; Robillard, M.S. Click-to-Release: Cleavable Radioimmunoimaging with [89Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio. Theranostics 2023, 13 (12), 4004-4015. DOI: 10.7150/thno.84865.

NLM
Vlastara M, Rossin R, Hoeben FJM, de Roode KE, Boswinkel M, Kleijn LHJ, Nagarajah J, Rijpkema M, Robillard MS. Click-to-Release: Cleavable Radioimmunoimaging with [89Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio. Theranostics 2023; 13(12):4004-4015. doi:10.7150/thno.84865. https://www.thno.org/v13p4004.htm

CSE
Vlastara M, Rossin R, Hoeben FJM, de Roode KE, Boswinkel M, Kleijn LHJ, Nagarajah J, Rijpkema M, Robillard MS. 2023. Click-to-Release: Cleavable Radioimmunoimaging with [89Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio. Theranostics. 13(12):4004-4015.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use